Freed AI vs Moderna
Side-by-side comparison of AI visibility scores, market position, and capabilities
San Francisco AI medical scribe delivering SOAP notes within 2 minutes of a visit; no EHR integration needed, making it immediately accessible to solo clinicians and small practices.
About
Freed AI is a San Francisco-based medical technology startup that provides clinicians with an AI-powered medical scribe accessible via mobile app that records patient visit audio, transcribes the conversation, and generates a complete SOAP note formatted for direct paste into any EHR. Freed differentiates from other ambient scribing tools through its simplicity and accessibility — clinicians start and stop recordings with a tap, and notes are delivered within 2 minutes without requiring EHR integrations or complex IT deployment. The product's one-tap workflow and near-immediate turnaround make it accessible to solo practitioners and small clinics that need ambient scribing without enterprise procurement processes. Freed's AI is designed to capture not just what was said but what was clinically significant, filtering conversation content to produce concise, structured notes rather than verbose transcriptions. The company has grown rapidly through physician word-of-mouth and healthcare professional communities, with thousands of clinicians using the product. Founded in 2022, Freed has gained traction as a lightweight, affordable alternative to enterprise ambient scribing platforms.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
About
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.